molecules of the month


oral serotonin-norepinephrine-dopamine reuptake inhibitor

approved in China for major depressive disorder

from serotinin-norepinephrine reuptake inhibitor, desvenlafaxine

Transl. Psychiatry, May 10, 2023

Luye Life Sciences

11 mins read

An Active Prodrug, Triple Reuptake Inhibitor for Major Depressive Disorder  While SNRIs and selective serotonin reuptake inhibitors (SSRIs) have been hugely successful in treating major depressive disorder (MDD), many patients remain resistant to treatment or do not experience full symptom relief. The majority of current treatments for MDD increase levels of synaptic serotonin and/or norepinephrine by inhibiting their reuptake transporters SERT and NET, respectively.  Ansofaxine (LY03005) is a new triple reuptake inhibitor (TRI) optimized from a serotonin-norepinephrine reuptake inhibitor (SNRI) by employing an interesting active prodrug strategy. In contrast to traditional prodrugs, which tend to be inactive on their own but release an active metabolite, LY03005 not only increases the exposure of its parent SNRI metabolite, desvenlafaxine, in the brain,…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: